Molecular docking, bioactivity, adme, toxicity risks, and quantum mechanical parameters of some 1,2-dihydroquinoline derivatives were calculated theoretically for investigation of its use as a pharmaceutical active ingredient in the treatment of multiple sclerosis (MS)
DOI:
https://doi.org/10.56782/pps.261Keywords:
1,2-dihydroquinoline derivatives, molecular docking, multiple sclerosis, ADME, quantum mechanical parametersAbstract
In this study, some 1,2-dihydroquinoline derivatives, which have not been synthesized before, were designed, and their usability in the treatment of multiple sclerosis (MS) was investigated. Firstly, a docking study was conducted between the designed molecules and the target proteins (3PP4, 6OBD, 7YXA, and 7TD4) that interact with drugs (International Nonproprietary Name (INN): Ocrelizumab, Alemtuzumab, and Siponimod) used in the treatment of MS. ADME (absorption, distribution, metabolism, and excretion) properties (Boiled Egg graph, bioavailability radar, physicochemical properties, lipophilicity, water solubility, pharmacokinetics, drug similarity, and medicinal chemistry) were analyzed. Bioactivity score, drug-likeness score, drug score, toxicity risks (mutagenic, tumorigenic, irritant, reproductive effective, fathead minnow LC50 (96 hours), daphnia magna LC50 (48 hours), oral rat LD50), bioconcentration factor, and density values were calculated. Quantum mechanical parameters include highest occupied molecular orbital energy (EHOMO), lowest unoccupied molecular orbital energy (ELUMO), chemical potential (μ), electron affinity (EA), global softness (S), global hardness (η), ionization potential (IP), total energy, dipole moments, and electrophilicity (ω) values were also calculated for all molecules. As a result of the data obtained from all these studies, (7-(diethylamino)-1,2-dihydroquinolin-3-yl)(6-(diethylamino)-2,3-dihydro-1H-indazol-1-yl)methanone was determined to be the most ideal molecule that can be used as a pharmaceutical active ingredient in the treatment of MS. Bond angles, bond lengths, Mulliken atomic charges, and molecular electrostatic potential (MEP) were calculated for this ideal molecule, and the structure of the molecule was explained in a multifaceted way.
Downloads
References
1. Taghour, M.S.; Elkady, H.; Eldehna, W.M.; El-Deeb, N.M.; Kenawy, A.M.; Elkaeed, E.B.; Alsfouk, A.A; Alesawy, M.S.; Metwaly, A.M.; Eissa, I.H. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J. Enzyme Inhib. Med. Chem. 2022, 37(1), 1903-1917. https://doi.org/10.1080/14756366. 2022.2085693 DOI: https://doi.org/10.1080/14756366.2022.2085693
2. Alzweiri, M.; Sweidan, K.; Saleh, O.A.; Al-Helo, T. Synthesis and evaluation of new 2-oxo-1,2-dihydroquinoline-3-carboxamides as potent inhibitors against acetylcholinesterase enzyme. Med. Chem. Res. 2022, 31(9), 1448-1460. https://doi.org/10.1007/s00044-022-02922-x DOI: https://doi.org/10.1007/s00044-022-02922-x
3. Huddar, S.; Park, C.M.; Kim, H.J.; Jang, S.; Lee, S. Discovery of 4-hydroxy-2-oxo-1,2-dihydroquinolines as potential inhibitors of Streptococcus pneumoniae, including drug-resistant strains. Bioorg. Med. Chem. Lett. 2020, 30(9), 127071-127074. https://doi.org/10.1016/j.bmcl.2020.127071 DOI: https://doi.org/10.1016/j.bmcl.2020.127071
4. Shahin, M.I.; Roy, J.; Hanafi, M.; Wang, D.; Luesakul, U.; Chai, Y.; Muangsin, N.; Lasheen, D.S.; El Ella, D.A.A; Abouzid, K.A.; Neamati, N. Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma. Eur. J. Med. Chem. 2018, 155, 516-530. https://doi.org/10.1016/j.ejmech.2018.05.042 DOI: https://doi.org/10.1016/j.ejmech.2018.05.042
5. Banu, S.; Bollu, R.; Naseema, M.; Gomedhika, P.M.; Nagarapu, L.; Sirisha, K.; Kumar, C.G.; Gundasw, S.K. A novel templates of piperazinyl-1,2-dihydroquinoline-3-carboxylates: Synthesis, anti-microbial evaluation and molecular docking studies. Bioorg. Med. Chem. Lett. 2018, 28(7), 1166-1170. https://doi.org/ 10.1016/j.bmcl.2018.03.007 DOI: https://doi.org/10.1016/j.bmcl.2018.03.007
6. Agwupuye, J.A.; Gber, T.E.; Edet, H.O.; Zeeshan, M.; Batool, S.; Duke, O.E.E.; Adah, P.O.; Odey, J.O.; Egbung, G.E. Molecular modeling, DFT studies and biological evaluation of methyl 2,8-dichloro-1,2-dihydroquinoline-3-carboxylate. Chem. Phys. Impact. 2023, 6, 100146-100157. https://doi.org/10.1016/j.chphi.2022.100146 DOI: https://doi.org/10.1016/j.chphi.2022.100146
7. Hayani, S.; Sert, Y.; Filali, Y.; Benhiba, F.; Chahdi, F.O.; Laraqui, F.Z.; Mague, J.T.; Ibrahimi, B.E.; Sebbar, N.K.; Rodi, Y.K.; Essassi, E.M. New alkyl (cyclohexyl) 2-oxo-1-(prop-2-yn-1-yl)-1, 2-dihydroquinoline-4-carboxylates: Synthesis, crystal structure, spectroscopic characterization, hirshfeld surface analysis, molecular docking studies and DFT calculations. J. Mol. Struct. 2021, 1227, 129520-129534. https://doi.org/10.1016/j.molstruc.2020. 129520 DOI: https://doi.org/10.1016/j.molstruc.2020.129520
8. Baltina, L.A.; Fairushina, A.I.; Baltina, L.A.; Eropkin, M.Y.; Konovalova, N.I.; Petrova, P.A.; Eropkina, E.M. Eropkina, EM (Eropkina, E. M.), Synthesis and antiviral activity of glycyrrhizic-acid conjugates with aromatic amino acids. Chem. Nat. Compd. 2022, 53(6), 1096-1100. https://doi.org/ 10.1007/s10600-017-2209-7 DOI: https://doi.org/10.1007/s10600-017-2209-7
9. Gaber, A.; Alsanie, W.F.; Alhomrani, M.; Alamri, A.S.; El-Deen, I.M.; Refat, M.S. Synthesis of 1-[(Aryl) (3-amino-5-oxopyrazolidin-4-ylidene)methyl ]-2-oxo-1,2-dihydroquinoline-3-carboxylic acid derivatives and their breast anticancer activity. Crystals 2021, 11(5), 571-582. https://doi.org/ 1096-1100.10.3390/ cryst11050571 DOI: https://doi.org/10.3390/cryst11050571
10. Kryl'skii, E.D.; Kravtsova, S.E.; Popova, T.N.; Matasova, L.V.; Shikhaliev, K.S.; Medvedeva S.M. 6-Hydroxy-2,2,4-trimethyl-1,2-dihydroquinoline demonstrates anti-inflammatory properties and reduces oxidative stress in acetaminophen-induced liver injury in rats. Curr. Issues Mol. Biol. 2023, 45(10), 8321-8336. https://doi.org/10.3390/ cimb45100525 DOI: https://doi.org/10.3390/cimb45100525
11. Zidan, T.A.; Yehia, A.A. Novel antioxidants based on polymerized 2,2,4-trimethyl-1,2-dihydroquinoline for styrene-butadiene rubber composites. J. Polym. Res. 2024, 31(6), 170-185. https://doi.org/10.1007/ s10965-024-04006-3 DOI: https://doi.org/10.1007/s10965-024-04006-3
12. Gorojankina, T.; Hoch, L.; Faure, H.; Roudaut, H.; Traiffort, E.; Schoenfelder, A.; Girard, N.; Mann, A.; Manetti, F.; Solinas, A.; Petricci, E.; Taddei, M.; Ruat, M. Discovery, Molecular and Pharmacological Characterization of GSA-10, a Novel Small-Molecule Positive Modulator of Smoothened. Mol. Pharmacol. 2013, 83(5), 1020-1029. https://doi.org/10.1124/ mol.112.084590 DOI: https://doi.org/10.1124/mol.112.084590
13. Lee, C.H.; Jin, H.; Lee, J.H.; Cho, H.J.; Kim, J.; Chung, K.C.; Jung, S.; Paik, S.R. Dequalinium-induced protofibril formation of α-synuclein. J. Biol. Chem. 2006, 281(6), 3463-3472. https://doi.org/10.1074/jbc.M505307200. DOI: https://doi.org/10.1074/jbc.M505307200
14. Kim, H.; Kim, B.J.; Koh, S.; Cho, H.J.; Jin, X.; Kim, B.G.; Choi, J.Y. High mobility group box 1 in the central nervous system: regeneration hidden beneath inflammation. Neural Regen. Res. 2025, 20(1), 107-115. https://doi.org/10.4103/NRR.NRR-D-23-01964 DOI: https://doi.org/10.4103/NRR.NRR-D-23-01964
15. Xue, Y.; Yin, P.; Chen, H.; Li, G.; Zhong, D. Novel peripheral blood mononuclear cell mRNA signature for IFN-beta therapy responsiveness prediction in multiple sclerosis. Autoimmunity 2024, 57(1), 1-12. https://doi.org/10.1080/08916934.2024.2332340 DOI: https://doi.org/10.1080/08916934.2024.2332340
16. Leussink, V.I.; Jankovic, M.; Growth, M.; Schuh, K.; Sauerbeck, I.S.; Hoffmann, O. Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-results from the MAGNON project. Brain Behav. 2024, 14(6), 1-11. https://doi.org/10.1002/brb3.3548 DOI: https://doi.org/10.1002/brb3.3548
17. Diem, L.; Ovchinnikov, A.; Friedli, C.; Hammer, H.; Kamber, N.; Chan, A.; Salmen, A.; Findling, O.; Hoepner, R. Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers. Mult. Scler. Relat. Disord. 2024, 86, 1-7. https://doi.org/10.1016/j.msard.2024.105570 DOI: https://doi.org/10.1016/j.msard.2024.105570
18. Hassan, S.S.; Darwish, E.S.S.; Ahmed, G.K.K.; Azmy, S.R.R.; Haridy, N.A.A. Relationship between disability and psychiatric outcome in multiple sclerosis patients and its determinants. Egypt. J. Neurol. Psychiatry Neurosurg. 2023, 59(1), 105-118. https://doi.org/10.1186/s41983-023-00702-x DOI: https://doi.org/10.1186/s41983-023-00702-x
19. Curran, C.; Vaitaitis, G.; Waid, D.; Volmer, T.; Alverez, E.; Wagner, D.H. Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS). J. Neuroimmunol. 2023, 374, 578008-578019. https://doi.org/10.1016/j.jneuroim.2022.578008 DOI: https://doi.org/10.1016/j.jneuroim.2022.578008
20. Rath, L.; Vijiaratnam, N.; Skibina, O. Alemtuzumab (Lemtrada) in multiple sclerosis: lessons from social media in enhancing patient care. Mult. Scler. J. 2016, 22(3), 335-355.
21. Uosef, A.; Vaughn, N.; Chu, X.; Elshawwaf, M.; Abdelshafy, A.A.A.; Elsaid, K.M.K.; Ghobrial, R.M.; Kloc, M. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages. Arch. Immunol. Ther. Exp. 2020, 68(3), 19-26. https://doi.org/10.1007/s00005-020-00584-4 DOI: https://doi.org/10.1007/s00005-020-00584-4
22. Burley, S.K.; Berman, H.M.; Christie, C.; Duarte, J.M.; Feng, Z.; Westbrook, J.; Young, J.; Zardecki, C. RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education. Protein Sci. 2018, 27(1), 316-330. https://doi.org/10.1016/j.bpj.2018. 11.1783 DOI: https://doi.org/10.1002/pro.3331
23. Wang, Y.; Lu, J.; Xiao, H.; Ding, L.; He, Y.; Chang, C.; Wang, W. Mechanism of Valeriana Jatamansi Jones for the treatment of spinal cord injury based on network pharmacology and molecular docking. Medicine 2023, 102(50), 1-9. https://doi.org/10.1097/MD. 0000000000036434 DOI: https://doi.org/10.1097/MD.0000000000036434
24. Ni, X.; Bao, H.; Guo, J.; Li, D.; Wang, L.; Zhang, W.; Sun, G. Discussion on the mechanism of Danggui Sini decoction in treating diabetic foot based on network pharmacology and molecular docking and verification of the curative effect by meta-analysis. Front. Endocrinol. 2024, 15, 1-14. https://doi.org/10.3389/fendo.2024.1347021 DOI: https://doi.org/10.3389/fendo.2024.1347021
25. Loganathan, V.; Akbar, I.; Ahamed, A.; Alodaini, H.A.; Hatamleh, A.A.; Abuthkir, M.H.S.; Gurusamy, R. Synthesis, antimicrobial and cytotoxic activities of tetrazole N-Mannich base derivatives: Investigation of DFT calculation, molecular docking, and Swiss ADME studies. J. Mol. Struct. 2024, 1300, 1-13. https://doi.org/10.1016/j.molstruc.2023. 137239 DOI: https://doi.org/10.1016/j.molstruc.2023.137239
26. Jarupula, V.; Kumar, E.P.; Bujji, S.; Shivarathri, P.; Neeradi, S.; Morthad, M.; Reddy, K.L. Synthesis of novel hybrids containing 1,2,3-triazole-linked tetrazole moieties, evaluation of anticancer activity and molecular docking studies. Russ. J. Gen. Chem. 2023, 93(4), 849-857. https://doi.org/10.1134/ S1070363223170012 DOI: https://doi.org/10.1134/S1070363223170012
27. Ganjo, A.R.; Adham, A.N.; Al-Bustany, H.A.; Aka, S.T. Phytochemical analysis and evaluation of antibacterial activity of Moringa oleifera extracts against gram-negative bacteria: an in vitro and molecular docking studies. Curr. Issues Pharm. Med. Sci. 2022, 35(4), 198-205. https://doi.org/10.2478/cipms-2022-0035 DOI: https://doi.org/10.2478/cipms-2022-0035
28. Daina, A.; Michielin, O.; Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7(42717), 1-13. https://doi.org/10.1038/srep42717 DOI: https://doi.org/10.1038/srep42717
29. Pirzada, A.S.; Khan, H.; Alam, W.; Darwish, H.W.; Elhenawy, A.A.; Kuznetsov, A.; Daglia, M. Physicochemical properties, pharmacokinetic studies, DFT approach, and antioxidant activity of nitro and chloro indolinone derivatives. Front. Chem. 2024, 12, 1-15. https://doi.org/10.3389/fchem.2024.1360719 DOI: https://doi.org/10.3389/fchem.2024.1360719
30. Yousuf, M. Advances in in-silico based predictive in-vivo profiling of novel potent β-glucuronidase inhibitors. Curr. Cancer Drug Targets 2019, 19(11), 906-918. https://doi.org/10.2174/15680096196661 90320102238 DOI: https://doi.org/10.2174/1568009619666190320102238
31. Kumar, A.S.; Bhaskara, B.L. Computational and spectral studies of 3,3′-(propane-1,3-diyl) bis(7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one). Heliyon 2019, 5(9), 1-10. https://doi.org/10.1016/j.heliyon.2019.e02420 DOI: https://doi.org/10.1016/j.heliyon.2019.e02420
32. Morak-Mlodawska, B.; Jelen, M.; Martula, E.; Korlacki, R. Study of lipophilicity and adme properties of 1,9-diazaphenothiazines with anticancer action. Int. J. Mol. Sci. 2023, 24(8), 6970-6981.https://doi.org/ 10.3390/ijms24086970 DOI: https://doi.org/10.3390/ijms24086970
33. Islamoğlu, F.; Hacıfazlıoğlu, E. Investigation of the usability of some triazole derivative compounds as drug active ingredients by adme and molecular docking properties. Mor. J. Chem. 2022, 10(4), 861-880. https://doi.org/10.48317/IMIST.PRSM/morjchem-v10i3.30855
34. Kuchana, M.; Kaparthi, K. Prediction of physicochemical properties, bioactivity, pharmacokinetics, drug-likeness and synthetic accessibility of phenyl and isoxazole azo dyes. Biosci. Biotechnol. Res. Commun. 2021, 14(5), 301-305. https://doi.org/10.21786/bbrc/14.5/53. DOI: https://doi.org/10.21786/bbrc/14.5/53
35. Al-Warhi, T.; Said, M.A.; El Hassab, M.A.; Aljaeed, N.; Ghabour, H.A.; Almahli, H.; Eldehna, W.M.; Abdel-Aziz, H.A. Unexpected synthesis, single-crystal x-ray structure, anticancer activity, and molecular docking studies of certain 2-((imidazole/benzimidazol-2-yl)thio)- 1-arylethanon es. Crystals 2020, 10(6), 446-464. https://doi. org/10.3390/cryst10060446 DOI: https://doi.org/10.3390/cryst10060446
36. Yussoff, M.A.M.; Hamid, A.A.A.; Hamid, S.A.; Halim, K.B.A. Computational quest for finding potential ebola vp40 inhibitors: a molecular docking study. Sains Malays. 2020, 49(3), 537-544. https://doi.org/10.17576/jsm-2020-4903-08 DOI: https://doi.org/10.17576/jsm-2020-4903-08
37. Prabha, B.; Ezhilarasi, M.R. Synthesis, spectral characterization, in vitro and in silico studies of benzodioxin pyrazoline derivatives. Biointerface Res. Appl. Chem. 2021, 11(2), 9126-9138. https://doi.org/10.33263/BRIAC112.91269138 DOI: https://doi.org/10.33263/BRIAC112.91269138
38. Ahn, S.; Truong, V.N.P.; Kim, B.; Yoo, M.; Lim, Y.; Cho, S.K.; Koh, D. Design, synthesis, and biological evaluation of chalcones for anticancer properties targeting glycogen synthase kinase 3 beta. Appl. Biol. Chem. 2022, 65(17), 1-14. https://doi.org/10. 1186/s13765-022-00686-x DOI: https://doi.org/10.1186/s13765-022-00686-x
39. Singh, S.; Gupta, A.K.; Chattree, A.; Verma, A. Lead finding from whole plant of curcuma longa with oxidative potential. Int. J. Pharm. Sci. Res. 2013, 4(8), 3142-3146. https://doi.org/10.13040/IJPSR.0975-8232.4(8).3142-46 DOI: https://doi.org/10.13040/IJPSR.0975-8232.4(8).3142-46
40. Silva, Y.K.C.; Reyes, C.T.M.; Rivera, G.; Alves, M.A.; Barreiro, E.J.; Moreira, M.S.A.; Lima, L.M. 3-aminothiophene-2-acylhydrazones: non-toxic, analgesic and anti-inflammatory lead-candidates. Molecules 2014, 19(6), 8456-8471. https://doi.org /10.3390/molecules19068456 DOI: https://doi.org/10.3390/molecules19068456
41. Vaugelade, S.D.; Nicol, E.; Vujovic, S.; Bourcier, S.; Pirnay, S.; Bouchonnet, S. UV-vis degradation of α-tocopherol in a model system and in a cosmetic emulsion-Structural elucidation of photoproducts and toxicological consequences. J. Chromatogr. A. 2017, 1517, 126-133. https://doi.org/10.1016/j.chroma.2017.08.015 DOI: https://doi.org/10.1016/j.chroma.2017.08.015
42. Sharma, D.; Thakur, A.; Sharma, M.K.; Sharma, R.; Kumar, S.; Sihmar, A.; Dahiya, H.; Jhaa, G.; Kumar, A.; Sharma, A.K.; Om, H. Effective corrosion inhibition of mild steel using novel 1,3,4-oxadiazole--pyridine hybrids: Synthesis, electrochemical, morphological, and computational insights. Environ. Res. 2023, 234(116555), 1-21. https://doi.org/10.1016/j. envres.2023.116555 DOI: https://doi.org/10.1016/j.envres.2023.116555
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Fatih Islamoğlu
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
